FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
esmo - Evidence for efficacy is based on the results of the RASolute 302 study
AI Summary: The FDA has approved daraxonrasib for metastatic pancreatic adenocarcinoma following RASolute‑302 trial data showing improved outcomes versus chemotherapy, with subgroup analyses providing further context. The approval offers a rare targeted option for a stubborn disease, though real‑world impact will hinge on access, biomarkers, and tolerability.
Related Stories
New drug doubles one-year survival in metastatic pancreatic cancer / 6 months
FDA grants early access to experimental pancreatic cancer drug / 5 months
Map of daraxonrasib resistance points to combo strategies in pancreatic cancer / 2 months
FDA approves Replimune’s Tudriqev after repeated rejections / 2 months
FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 4 months
FDA to revisit Atara/Pierre Fabre cell therapy approval for rare lymphoma / 5 months
FDA advisory panel rejects camizestrant after SERENA‑6 results / 5 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pancreatic Cancer, Biotech, Pharmaceuticals, Cancer Screening and look for the RSS link.
StackHealth Time Machine